<table>
<thead>
<tr>
<th>Title</th>
<th>Nuclear Localization Marker of FOXO3a: Can it be Used to Predict Doxorubicin Response?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Gong, C; Khoo, US</td>
</tr>
<tr>
<td>Citation</td>
<td>Frontiers in Oncology, 2013, v. 3, p. 149</td>
</tr>
<tr>
<td>Issued Date</td>
<td>2013</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10722/186466">http://hdl.handle.net/10722/186466</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.; This Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission.</td>
</tr>
</tbody>
</table>
Nuclear localization marker of FOXO3a: can it be used to predict doxorubicin response?

Chun Gong and Ui-Soon Khoo*

Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

*Correspondence: uskhoo@pathology.hku.hk

A commentary on


Forkhead box O (FOXO) proteins, a subgroup of transcription factors characterized by a conserved DNA-binding forkhead domain. FOXO3a is one of the members of this subfamily which activate or repress multiple genes involved in cell cycle regulation, apoptosis, DNA damage repair, protection against oxidative stress, and metabolism. FOXOs are regulated by a broad variety of stimuli which control FOXO protein expression, subcellular localization, DNA binding, and transcriptional activity. The biological activity of FOXO proteins are primarily regulated by post-translational modifications, including phosphorylation, acetylation, and ubiquitination.

The PI3K/Akt (PKB) pathway is one of the first and potentially most important kinase pathways shown to regulate FOXO3a activity (Paradis and Ruvkun, 1998). Phosphorylation of FOXO3a by Akt results in cytoplasmic accumulation and its subsequent degradation. ERK (Biggs et al., 1999; Yang et al., 2008) and JNK (Sunters et al., 2006), two of the three canonical MAPK pathways (ERK, p38, and JNK), have also been shown to activate FOXO3a activity, but nothing had previously been known with regard to p38 MAPK signaling pathway in relation to FOXO protein regulation. Phosphorylations at most of the known sites of FOXO3a lead to its translocation into cytoplasm and inactivation (Yang and Hung, 2009). Based on this, functional studies of FOXO3a could only examine its activity indirectly through checking the expression of its inactive form.

FOXO3a has been shown to play an important role in mediating the cytotoxic effects of chemotherapeutic drugs such as doxorubicin (Hui et al., 2008a,b). It has been observed that acquisition of chemoresistance correlated unexpectedly with increased expression and nuclear accumulation of FOXO3a in leukemic cells (Hui et al., 2008b) and breast cancer cells (Chen et al., 2010). Indeed, examination in breast cancer tissue microarrays showed sustained nuclear FOXO3a was associated with poor prognosis (Chen et al., 2010). It is speculated that FOXO3a engages in a feedback mechanism whereby sustained FOXO3a activation can enhance hyperactivation of the PI3K/Akt pathway (Gomes et al., 2008).

Lam and co-workers in the captioned article, report a novel phosphorylation site of FOXO3a which appears responsible for its nuclear relocation under the action of doxorubicin (Ho et al., 2012). They observed FOXO3a nuclear relocation as well as induction of p38 expression following doxorubicin treatment and hypothesized that p38 could directly regulate FOXO3a and provided concrete evidence to support their speculation. They elegantly demonstrated that p38 not only complexes with FOXO3a with or without doxorubicin treatment, but also directly phosphorylates FOXO3a at a novel site, Ser-7. Phosphorylation of FOXO3a at Ser-7 is a key for its relocation to nucleus, as a Ser-7 phosphorylation-deficient mutant could not be localized to nucleus when treated with doxorubicin (Ho et al., 2012).

The involvement of the stress activated kinase p38 targeting FOXO3a opens further horizons for investigation with regard to other p38 phosphorylation sites that may contribute toward FOXO3a nuclear relocalization. Indeed additional p38 phosphorylation sites were identified in this study which are also targeted by JNK and ERK. Furthermore p38 phosphorylation may also have other biological functions not yet identified. In terms of anti-cancer therapeutics, due to the potent antitumor activity of FOXO3a, it has been suggested that drugs that activate FOXO3a may be used in combination with other therapeutic agents to sensitize tumor cells. The dependence of chemotherapeutic-induced cell death on p38 activation is well documented.

Ser-7 is the first reported site at which phosphorylation can lead to the nuclear localization of FOXO3a. It could serve as a marker for nuclear FOXO3a as suggested by the authors. However, caution should be taken when using it as a marker for active FOXO3a, for though it is generally acknowledged that nuclear FOXO3a is active, this should not be taken for granted. The authors did not show directly that the phosphorylation at Ser-7 was a causal event of FOXO3a activation. As shown in their supplementary data, over-expression of Ser-7 phosphorylation-deficient mutants could still induce the activation of FOXO3a and the expression of its target genes (Ho et al., 2012). Hence the functional importance of Ser-7 phosphorylated FOXO3a remains to be further investigated.

This article mainly used MCF7, a doxorubicin-sensitive breast cancer cell line, as a model. However, the functions of FOXO3a have been indicated to change from pro-apoptotic to pro-survival in cell lines with acquire resistance to doxorubicin (Hui et al., 2008a; Wilson et al., 2011). Therefore, besides fully exploring the functions of nuclear Ser-7 phosphorylated FOXO3a in the current cell line model, it would also be interesting to study the role of FOXO3a phosphorylation at Ser-7 in acquired doxorubicin resistance. It was noted that Ser-7 phosphorylation by doxorubicin also occurs in prostate cancer cell lines, and was suggested that it may be a universal event. As mentioned
earlier, nuclear accumulation of FOXO3a and hyper-active PI3K-AKT pathway as observed with acquisition of doxorubicin resistance in both doxorubicin-resistant breast cancer cell line and leukemic cell line (Hui et al., 2008a,b; Chen et al., 2010). Is the nuclear localization of FOXO3a in the Doxorubicin-resistant cells is also caused by Ser-7 phosphorylation or is there any other mechanism? Is the Ser-7-phosphorylated FOXO3a functionally active in mediating the drug resistance? More importantly, can this marker be used in predicting doxorubicin response of tumor cells? Such application would be clinically useful in guiding the choice of chemotherapeutic regime.

The authors report they confirm that p38 mediates FOXO3a phosphorylation on Ser-7 in vivo, by the use of a phospho-specific antibody, anti-P-FOXO3a-(Ser-7) which they had generated and validated. This in vivo study however was performed on MCF7 breast cancer cell lines that were co-transfected with pCMV-FLAG-FOXO3a and increasing amounts of pEGFP-p38α. It could be argued that this disagrees with the conventional definition of in vivo study, as “in vivo” generally refers to using whole, living organisms whilst cell line study is usually considered as “in vitro”. Regardless, this article presented solid evidences to support the definitive conclusion that p38 directly phosphorylated FOXO3a at Ser-7 and provides new insights into the regulation of FOXO3a. Furthermore, it has provided a nuclear FOXO3a marker, anti-P-FOXO3a-(Ser-7) which has high potential for application on clinical samples, thus implicating some very interesting and worthwhile further research directions.

REFERENCES